Gsk (GSK) EV to FCF (2026)

Gsk (GSK) has 18 years of EV to FCF data on file, last reported at 6.39 in Q3 2026.

• For the quarter ending Q3 2026, EV to FCF changed N/A year-over-year to 6.39; the trailing twelve-month figure through Sep 2026 stood at 6.39 (changed N/A YoY), and the FY2025 full-year result was 8.32, up 25.28% from the prior year.
• EV to FCF was 6.39 for Q3 2026 at Gsk, down from 7.53 in the prior quarter.
• In the past five years, EV to FCF ranged from a high of 9.73 in Q1 2024 to a low of 4.45 in Q3 2022.
• A 5-year average of 7.48 and a median of 7.52 in 2023 frame the typical range for EV to FCF.
• Across the five-year window, EV to FCF soared 66.11% in 2023 and tumbled 30.92% in 2024, its largest moves.
• Gsk's EV to FCF stood at 5.76 in 2022, then soared by 66.11% to 9.57 in 2023, then tumbled by 30.92% to 6.61 in 2024, then increased by 20.24% to 7.95 in 2025, then declined by 19.58% to 6.39 in 2026.
• Per Business Quant data, the three most recent EV to FCF figures were 6.39 in Q3 2026, 7.53 in Q2 2026, and 8.93 in Q1 2026.